Skip to content
Evigrade
CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Triptan, selective 5HT1B/1D receptor agonist

Updated · Methodology

Mechanism

Zolmitriptan selectively stimulates the serotonin receptors that mediate vascular contraction, and in animal studies it constricts the carotid arteries. Ergotamine also constricts arteries and on its own can cause myocardial ischaemia, or rarely infarction, even in people with no known heart disease. Vasospasm after ergot drugs can be prolonged, and the vasoconstrictor effects of the two drugs may add up. In studies in healthy volunteers, ergotamine did not change the pharmacokinetics of zolmitriptan or its active metabolite, so the danger of the combination lies in the blood vessels, not in drug levels. The Spanish zolmitriptan summary of product characteristics (SmPC) calls the higher risk of coronary artery spasm a theoretical possibility and still contraindicates the combination.

Symptoms

Heaviness, tightness, pain or pressure in the chest, throat, neck or limbs is common after zolmitriptan. These sensations usually appear within 4 hours, pass on their own and are not cardiac. In very rare cases, however, zolmitriptan causes coronary artery spasm, angina or myocardial infarction. Bowel ischaemia or infarction presents with abdominal pain and bloody diarrhoea. Splenic infarction can also occur, and blood pressure may rise for a short time. Vasospasm from ergotamine starts with numbness and tingling in the fingers and toes, headache and pain over the heart. In ergotism the limbs hurt and turn blue, their pulses disappear, and without treatment gangrene develops.

Management

The zolmitriptan documents of the Spanish Agency of Medicines and Medical Devices (AEMPS) and the US Food and Drug Administration (FDA) contraindicate the combination. The Spanish summary of product characteristics (SmPC) for ergotamine with caffeine contraindicates triptans as a class and names zolmitriptan among the triptans that raise the risk of vasospasm (AEMPS). Take zolmitriptan no sooner than 24 hours after an ergotamine product (zolmitriptan SmPC, AEMPS, and label, FDA). In the other order, the Spanish SmPC advises waiting at least 6 hours after zolmitriptan, while the US label does not allow the two drugs within 24 hours of each other (zolmitriptan SmPC, AEMPS, and label, FDA). If ergotamine has not stopped the attack, do not add a triptan for the same attack (ergotamine with caffeine SmPC, AEMPS). If chest pain or other signs of cardiac ischaemia appear after a zolmitriptan dose, give no further doses until the patient has had a cardiac assessment (zolmitriptan SmPC, AEMPS). If numbness or tingling in the fingers, pain over the heart or other signs of vasospasm appear, stop ergotamine at once and start a peripheral vasodilator. For severe vasospasm, give the peripheral vasodilator intravenously (ergotamine with caffeine SmPC, AEMPS). Stop zolmitriptan if arrhythmias occur. If abdominal pain with bloody diarrhoea or white fingers appear, rule out vasospasm before the next dose. Monitor blood pressure during treatment (zolmitriptan label, FDA). Taking acute migraine drugs on 10 or more days a month can make headaches more frequent (zolmitriptan label, FDA). If medication overuse headache is suspected, stop the treatment (zolmitriptan SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ergotamine

Other interactions with Zolmitriptan